

Revisions to APF24 Cautionary advisory labels



Label 5 revised explanatory notes

5 Ask your doctor or pharmacist before using any other medicine including over-the-counter medicines or health products.

Label 5 is recommended for medicines that are the *cause* of interactions with other medicines, potentially leading to therapeutic failure or adverse effects. The mechanism of these interactions is commonly via enzyme inhibition or induction that alters the metabolic clearance of the affected medicines.

Label 5 is also recommended for medicines that have a narrow therapeutic index, such that an interaction with another medicine is likely to be severe enough to cause a clinically significant outcome (see 'Drug interactions', page 111).

Label 5 is also recommended for angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), because the potential for renal impairment increases when ACEIs or ARBs are used concurrently with non-steroidal anti-inflammatory drugs (NSAIDs, including cyclo-oxygenase-2 (COX-2) inhibitors), except low dose aspirin. In addition, the concurrent use of an ACEI or ARB, an NSAID and a diuretic (the 'triple whammy') can result in acute kidney injury (see 'Drug interactions', page 111).

This label is intended to alert patients that, while taking this medicine, they should consult their doctor or pharmacist before using any other medicines, including non-prescription or complementary medicines. When dispensing a medicine that requires label 5, assess the patient's medication regimen to determine whether there are any potential interactions that should be avoided or that require close monitoring.

Some complementary medicines have the potential to interact with other medicines, and patients must be warned of this when taking these products (see 'Complementary medicines monographs', page 486).

Consult 'Drug interactions', page 111, a medicines information reference or the approved Product Information for more details.

Label 12 revised explanatory notes

12 This medicine may affect mental alertness and/or coordination. If affected, do not drive a motor vehicle or operate machinery.

Label 12 is recommended for medicines with the potential to cause CNS disturbances (e.g. dizziness, light-headedness, fatigue) and impair psychomotor performance. These symptoms frequently disappear with continued therapy. However, certain individuals (e.g. the elderly or patients taking multiple medicines) may be more susceptible to these effects.

Impaired motor coordination is associated with significant risks to driver, passenger and pedestrian safety. Label 12 should be used to raise awareness of this important safety issue.

Children receiving medication requiring label 12 may experience impaired alertness and coordination when undertaking physical activities such as riding a bicycle. Parents and children should be advised accordingly.


In certain cases, label 12 is appropriate only on initiation of therapy or when the dose is increased.

When dizziness is caused by orthostatic hypotension, Label 16 should be used.

Label K revised explanatory notes

K FOR EXTERNAL USE ONLY

Add the words 'For external use only'. This additional instruction is recommended for medicines that are to be applied topically to the skin (e.g. creams, ointments, lotions). Label K is not recommended for creams/ointments/lotions/gels which are to be administered within a body cavity (e.g. via the nasal, rectal or vaginal routes).



Revisions to Table A2. Recommended cautionary advisory labels for medicines

Revised CAL recommendations for the following medicines are shown in the table below.

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|---|--|
| Abacavir | Oral solution: 7b (60 days), 12†, 21 Tablet: 12†, 21, A |
| Aciclovir | Eye ointment: 7b (28 days) Tablet: D |
| Aclidinium | 7b (90 days) |
| Adapalene | 8, 21, K |
| Alirocumab | 6, 13 |
| Amisulpride | Oral solution: 1, 7b (60 days), 12, 16 Tablet: 1, 12, 16 |
| Amoxicillin | Capsule/tablet: D Oral suspension: 6*, 7a (14 days), D, J |
| Amoxicillin, clavulanic acid | Oral suspension: 6, 7a (7 days), D, F, J Tablet: 13, D, F |
| Atenolol | Oral solution: 7b (30 days), 9, 12†, 13, 16†, I Tablet: 9, 12†, 16†, I |
| Atovaquone | Oral suspension: B, D, J Tablet: B, D |
| Atovaquone, proguanil | 4a (delete dairy products), B, D |
| Azathioprine | 8, 13, 21, A, B |
| Azithromycin | Capsule/tablet: D Oral suspension: 7a (10 days), D, J |
| Bazedoxifene, estrogens (conjugated) | 7b (60 days), 12, 13, 21, A |
| Besifloxacin | 7b (28 days), J |
| Bicalutamide | 5, 12, 13, 21, A |
| Bimatoprost | Eye drop (multi-dose): 7b (28 days) Eye drop (single-dose): 7b (30 days) |
| Bisacodyl | Enema/suppository: L Tablet: A |
| Brexpiprazole | 12†, 16†, I |
| Brinzolamide | 7b (28 days), J |
| Budesonide | Capsule/tablet: 9, 18, A Inhaler/nebule: 14, J* Rectal foam: 7b (28 days), 18, J |
| Buprenorphine | Patch: 1, 21, K Sublingual film/sublingual tablet: 1, 13 |
| Bupropion | 5, 12†, A |
| Bupropion, naltrexone | 5, 12†, A, B |
| Calcipotriol | 8, K |
| Candesartan | 5, 11, 12†, 16†, 21, A |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|--|--|
| Captopril | Oral solution: 3b, 5, 6, 7b (28 days), 11, 12†, 16†, 21 Tablet: 3b, 5, 11, 12†, 13, 16†, 21, A |
| Carbamazepine | Oral suspension: 5, 9, 12†, 13, 18, 21, B, J Tablet: 5, 9, 12†, 13, 18, 21, A, B |
| Carglumic acid | 6*, 7b (30 days), 13, F |
| Cefaclor | Modified-release tablet: A, B, D Oral suspension: 6, 7a (14 days), D, J |
| Cefalexin | Capsule: D Oral suspension: 6, 7a (14 days), D, J |
| Cefuroxime | Oral suspension: 6*, 7a* (10 days) B, D, J Tablet: B, D |
| Cetrorelix | 13, 21 |
| Chloramphenicol | Ear/eye drop (multi-dose)/eye ointment: 7b (28 days), 21 Eye drop (single dose): 6, 13, 21 |
| Chlorpromazine | Oral solution: 1, 8, 9 (long-term regular therapy), 13, 16 Tablet: 1, 8, 9 (long-term regular therapy), 13, 16, A |
| Choriogonadotropin | 6, 13, 21 |
| Ciclosporin | Capsule: 5, 8, 9, 18, 21, A Oral solution: 5, 7b (60 days), 8, 9, 18, 21 |
| Ciprofloxacin | Ear/eye drop: 7b (28 days), J Tablet: 3b, 4a, 5, 8, 12, D |
| Cladribine | Tablet: 13, 21, A |
| Clarithromycin | Oral suspension: 5, 7a (14 days), D, J Tablet: 5, D |
| Clindamycin | Capsule: D Lotion: J, K Topical solution: 7b (90 days), K Vaginal cream: D, L |
| Clobazam | 1 or 1a, 9 |
| Clotrimazole | Cream: E Pessary/vaginal cream: D*, L Topical solution: E, K |
| Clozapine | Oral suspension: 1, 7b (90 days), 9, 12, 13, 16, J Tablet: 1, 9, 12, 13, 16 |
| Dapagliflozin | 10a, 16, 21, A |
| Dapsone | Gel: 7b (98 days), K Tablet: B |
| Deferasirox | Dispersible tablet: 3b, 4a (delete dairy products), 13 Tablet: 4a (delete dairy products), 13, A |
| Deferiprone | Oral solution: 4a, 5, 6, 7b (35 days), 13, 21, B Tablet: 4a, 5, 13, 21, B |
| Denosumab | 6, 13, 21 |
| Dexamethasone | Eye drop: 7b (28 days), 9 (except short courses), J Tablet: 9 (except short courses), B |
| Dexamethasone, framycetin, gramicidin | Ear drop: 7b (28 days), 21 |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|-------------------------------------|---|
| Diazepam | Oral solution: 1, 7b (90 days), 9 Tablet: 1, 9 |
| Diclofenac | Capsule/enteric-coated tablet/modified-release tablet: 10a, 12†, 19b, A, B Eye drop: 7b (28 days) Gel: 8*, K Oral solution/tablet: 10a, 12†, 19b, B Suppository: 10a, 12†, 19b, L |
| Dienogest | 13, 21, A |
| Dorzolamide | Eye drop: 7b (28 days) |
| Efavirenz | Oral solution: 3b, 5, 12†, 21 Tablet: 3b, 5, 12†, 21, A |
| Enalapril | 5, 11, 12†, 16†, 21, A |
| Eprosartan | 5, 11, 12†, 16†, 21, A |
| Erythromycin ethyl succinate | Oral suspension: 5, 6, 7a (10 days), 18, D, J Tablet: 5, 18, D |
| Escitalopram | Oral solution: 5, 7b (60 days), 9, 12 Tablet: 5, 9, 12 |
| Estradiol | Gel/patch: 21, K Pessary: 13, 21, L Tablet: 21, A |
| Exenatide | 6 (except pen in use), 7b* (30 days), 10a, 13, 20* |
| Fentanyl | Lozenge/orally disintegrating tablet/sublingual tablet: 1, 5, 13, 21 Nasal spray: 1, 5, 21 Patch: 1, 5, 21, K |
| Ferrous fumarate | 4a (delete dairy products), 13 |
| Fexofenadine | Oral suspension: I, J Tablet: I |
| Flucloxacillin | Capsule: 3a or 3b, D Oral suspension: 3a or 3b, 6, 7a (14 days), D, J |
| Fluconazole | Capsule (multi-dose): 5, 21, A, D Capsule (single-dose): 5, 21, A Oral suspension: 5, 7a (14 days), 21, D, J |
| Fluorouracil | 8, 21, K |
| Fluticasone | Inhaler/nebule: 14 Nasal drops/nasal spray: J |
| Follitropin alfa | 6* (except carton in use), 7a*, 12, 13, 21 |
| Follitropin delta | 6* (except carton in use), 7b (28 days), 13, 21 |
| Fosinopril | 5, 11, 12†, 16†, 21, A |
| Framycetin | Eye drop: 7b (28 days), 21 |
| Furosemide (frusemide) | Oral solution: 3b, 7b (56 days), 16 Tablet: 3b, 16 |
| Ganirelix | 13, 21 |
| Gentamicin | Eye drop: 7b (28 days), 21 |
| Glyceryl trinitrate | Ointment/sublingual spray: 16 Patch: 13, 16, 21, K Sublingual tablet: 7b* (90 days), 13, 16 |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|--|---|
| Goserelin | 13, 21 |
| Gramicidin, neomycin, nystatin, triamcinolone | Ear drop: 6, 21 Ear ointment: 21 Ointment: 21, K |
| Hydrochlorothiazide | 8, 16 |
| Hydrochlorthiazide, triamterene | 8, 11, 16, B |
| Hydrocortisone | Cream/gel/ointment/topical solution: K Eye ointment: 7b (28 days) Rectal foam: 9, J Tablet: 9, B |
| Hyoscine | Solution for injection/tablet: 12 Suppository: 12, L |
| Ibuprofen | Capsule/tablet: 10a, 12†, 19b, B Oral suspension: 10a, 12†, 19b, B, J |
| Indometacin | Capsule: 10a, 12†, 19b, A, B Suppository: 10a, 12†, 19b, L |
| Ingenol | 6, K |
| Insulins | 6 (except cartridge/vial in use), 7b (28 days), 10a |
| Interferon beta-1a | Powder for injection: 12, 13, 21 Solution for injection: 6, 7b*(21 days), 12, 13, 21 |
| Irbesartan | 5, 11, 12†, 16†, 21, A |
| Isosorbide dinitrate | 16 |
| Isosorbide mononitrate | Modified-release tablet: 16, A* |
| Ivacaftor | Granules: 5, 12, 18, B Tablet: 5, 12, 18, A, B |
| Ivacaftor, lumacaftor | Granules: 5, 12, B Tablet: 5, 12, A, B |
| Ixazomib | 3b, 13, 20, 21, A |
| Ketoconazole | Cream: E, K Shampoo: K |
| Ketoprofen | Modified-release capsule: 10a, 12†, 19b, A, B Suppository: 10a, 12†, 19b, L |
| Lacosamide | Oral solution: 7b (60 days), 9, 12 Tablet: 9, 12 |
| Latanoprost | 7b (28 days) |
| Leuprorelin | 6, 12, 21 |
| Levodopa, decarboxylase inhibitor | Capsule/modified-release capsule/modified-release tablet: 4a (delete dairy products), 9, 16, A Intestinal gel: 6, 9, 13, 16 Tablet: 4a (delete dairy products), 9, 16 |
| Levonorgestrel | Tablet: 13, 21, A |
| Levothyroxine | 3b, 4a (delete dairy products), 6* |
| Liraglutide | 6, 7b (30 days), 21 |
| Lisinopril | 5, 11, 12†, 16†, 21, A |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|---|---|
| Losartan | 5, 11, 12†, 16†, 21, A |
| Lumacaftor with ivacaftor | See Ivacaftor, lumacaftor |
| Megestrol | 21, A |
| Mercaptopurine | Oral suspension: 4a (delete antacids and mineral supplements), 7b (56 days), 8, 21, J Tablet: 4a (delete antacids and mineral supplements), 8, 21, A |
| Mesalazine | Enema: 13 Enteric-coated tablet: 3b, 13, A Modified-release granules/tablet: 13, A Suppository: 13, L |
| Mesterolone | 21, A |
| Methotrexate | Solution for injection: 5, 8, 10a, 12, 13, 20 (weekly dosage schedule), 21 Tablet: 5, 8, 10a, 20 (weekly dosage schedule), 21, A |
| Metronidazole | Cream/gel: K Oral suspension: 2, 5, 13, C, D, J Suppository: 2, 5, D, L Tablet: 2, 5, 13, B, D Vaginal gel: D, L |
| Miconazole | Cream/lotion/ointment/powder/spray liquid: E, K Oral gel: 5, D Shampoo/tincture: K Spray powder: E, J, K |
| Mifepristone | 3b, 13, 18, 21, A |
| Minoxidil | Tablet: 16 |
| Misoprostol | Tablet: 3b*, 13, 21, A, B* |
| Morphine | Modified-release capsule/modified-release tablet: 1, A Modified-release granules/tablet: 1 Oral solution: 1, 7b (6 months) |
| Mycophenolate (mycophenolic acid) | Capsule/tablet: 4a (delete dairy products), 8, 9, 21, A Oral suspension: 4a (delete dairy products), 7a (60 days), 8, 9, 21, J |
| Nafarelin | 21 |
| Naproxen | Enteric-coated tablet/modified-release tablet: 10a, 12†, 19b, A, B Oral suspension/tablet: 10a, 12†, 19b, B, J |
| Nevirapine | Oral suspension: 5, 7b (6 months), 12†, 21, J Tablet: 5, 12†, 21, A |
| Nicotine | Chewing gum/inhaler/lozenge/oral spray: 21 Patch: 21, K Sublingual tablet: 21 |
| Norethisterone | 13, 21, A |
| Nystatin | Capsule/tablet: D Cream: E Oral suspension: D, J Vaginal cream: D, L |
| Olaparib | Capsule: 3b, 5, 6, 12, 13, 18, 21, A Tablet: 5, 12, 13, 18, 21, A |
| Olmesartan | 5, 11, 12†, 16†, 21, A |
| Olodaterol with/without tiotropium | 7b (90 days), 22 |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|-------------------------------|--|
| Ondansetron | Oral solution/tablet: 5 Orally disintegrating tablet/wafer: 5, 13 Suppository: 5, 13, L |
| Oseltamivir | Capsule: D Oral suspension: 6, 7a (17 days), D, J |
| Oxcarbazepine | Oral suspension: 5, 9, 12, 13, 21, J Tablet: 5, 9, 12, 13, 21 |
| Oxybutynin | Patch: 12, 13, 21, K Tablet: 12 |
| Oxycodone | Capsule/oral solution/tablet: 1, 18 Modified-release tablet: 1, 18, A Suppository: 1, L |
| Panobinostat | 12, 13, 16, 21, A, B, I |
| Pantoprazole | Enteric-coated tablet: A Granules: C |
| Paracetamol | Capsule/modified-release tablet: 13, 19a, A Oral solution/tablet: 13, 19a Oral suspension: 13, 19a, J Suppository: 13, 19a, L |
| Pegfilgrastim | 6, 13 |
| Perindopril | 5, 11, 12†, 16†, 21, A |
| Pheniramine | Eye drop: 7b (28 days) Tablet: 1, 13 |
| Phenoxyethylpenicillin | Capsule/tablet: 3a or 3b, D Oral suspension: 3a or 3b, 6, D, J |
| Phenytoin | Capsule: 5, 9, 12†, 13, 21, A Chewable tablet: 5, 9, 12†, 13, 21 Oral suspension: 5, 9, 12†, 13, 21, J |
| Piroxicam | Capsule/tablet: 10a, 12†, 19b, B Gel: K |
| Podophyllotoxin | 21, K |
| Pravastatin | 21, A |
| Prednisolone | Enema/suppository: 7b*(90 days), 13, L Eye drop: 6 Oral solution: 6*, 7b (28 days), 9 (except short courses), B Tablet: 9 (except short courses), B |
| Prochlorperazine | Suppository: 1, 13, 16, L Tablet: 1, 13, 16 |
| Progesterone | Capsule: 3b, 12, 21, A Cream: 12, 21 Pessary/vaginal capsule/vaginal gel: 12, 21, L |
| Propylthiouracil | 21, A |
| Quinapril | 5, 11, 12†, 16†, 21, A |
| Raloxifene | 21, A |
| Raltegravir | 4a (delete dairy products), 12† |
| Ramipril | 5, 11, 12†, 16†, 21, A |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|---|---|
| Ribavirin | Tablet: 5, 12, 13, 21, A, B |
| Rifaximin | No CALs |
| Rivastigmine | Capsule: 12, B Patch: 12, 21, K |
| Rosuvastatin | 21, A |
| Rotigotine | 1, 9, 12, 16, 21, K |
| Salbutamol | Capsule for inhalation: 22 Inhaler: J Nebule: 7b (90 days), 13 Oral solution: 13 |
| Sevelamer | Oral suspension: 13, B Tablet: 13, A, B |
| Sodium fusidate | Ointment: 7b (60 days), K Tablet: 3b, A, D |
| Sulfamethoxazole, trimethoprim | Oral suspension: 8, 11, B, D, J Tablet: 8, 11, B, D |
| Tazarotene | Cream: 7b (12 months), 8, 21, K Gel: 8, 21, K |
| Telmisartan | 5, 11, 12†, 16†, 21, A |
| Tenofovir alafenamide | 12† |
| Tenofovir disoproxil | 12†, B |
| Terbinafine | Cream/gel/topical solution: K Tablet: 5, 8, 13, D |
| Teriflunomide | 5, 21, A |
| Teriparatide | 6, 7b (28 days) |
| Testosterone | Capsule: 13, 21, A, B Cream: 7b (84 days), 21, K Gel: 7b*(60 days), 21, K Patch/topical solution: 21, K |
| Tibolone | 5, 21, A |
| Tiotropium | Capsule for inhalation: 7b* (5 days—strip in use), 13*, 22 Soft-mist inhaler: 7b (90 days) |
| Tipranavir | 5, 6 (except bottle in use), 7b (60 days) |
| Tobramycin | Capsule for inhalation: 13, 21, 22 Eye drop/eye ointment: 7b (28 days) Solution for inhalation: 6, 7b (28 days), 13, 21 |
| Toremifene | 12, 21, A |
| Trandolapril | 5, 11, 12†, 16†, 21, A |
| Tretinoin | Capsule: 8, 21, A, B Cream: 8, 21, K |
| Trimethoprim with sulfamethoxazole | See Sulfamethoxazole, trimethoprim |
| Ursodeoxycholic acid | Capsule/tablet: 4a, A Oral suspension: 4a, 7b (4 months), J |
| Valganciclovir | Oral solution: 6, 7a (49 days), 12†, 13, 21, B, J Tablet: 12†, 13, 21, A, B |

| Medicine | Revised ancillary label (number) and/or additional instruction (letter) |
|--------------|---|
| Valsartan | 5, 11, 12 [†] , 16 [†] , 21, A |
| Voriconazole | Oral suspension: 5, 7a (14 days), 8, 12, 21, C, D, J Tablet: 5, 8, 12, 21, A, C, D |

Revisions to Table A3. Hazardous medicines recommended to be labelled with cautionary advisory label 21

The explanatory notes for the superscripts to Table A3 (page 31) have been revised as follows:

- a. Antineoplastic medicines that are considered hazardous to all people handling them. Appropriate personal protective equipment (PPE) should be used, regardless of the formulation.
- b. Medicines that meet one or more of the following criteria:
 - carcinogenicity
 - genotoxicity
 - organ toxicity at low doses

Some of these medicines may also cause reproductive toxicity. Safety data sheets and other product information should be consulted to determine the appropriate precautions for all people to take when handling these medicines.

- c. Medicines that mainly pose a risk of reproductive toxicity, i.e. they increase the risk of adverse effects on sexual function or fertility in adult females and/or males, or on the development of the offspring (e.g. teratogenic effects). Women who are pregnant or breastfeeding, women who might become pregnant, and male partners of women who might become pregnant should avoid handling these medicines, or use appropriate PPE and techniques to minimise exposure to them.

The superscripts assigned to the following medicines in Table A3 have been revised as follows:

- Cyproterone^b
- Danazol^b
- Norethisterone^b
- Mesterolone^b
- Fotemustine^a
- Lenvatinib^a
- Midostaurin^a
- Raltitrexed^a

The following medicines have been deleted from Table A3 because they are no longer available in Australia:

- Gestrinone
- Teniposide
- Tetracycline